Using genetics to understand the role of kidney function in COVID-19: a mendelian randomization study
Abstract Background Kidney dysfunction occurs in severe COVID-19, and is a predictor of COVID-19 mortality. Whether kidney dysfunction causes severe COVID-19, and hence is a target of intervention, or whether it is a symptom, is unclear because conventional observational studies are open to confound...
Guardado en:
Autores principales: | , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
BMC
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/3c669e3ede624482ad9dd9feade77c76 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:3c669e3ede624482ad9dd9feade77c76 |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:3c669e3ede624482ad9dd9feade77c762021-11-14T12:43:55ZUsing genetics to understand the role of kidney function in COVID-19: a mendelian randomization study10.1186/s12882-021-02586-61471-2369https://doaj.org/article/3c669e3ede624482ad9dd9feade77c762021-11-01T00:00:00Zhttps://doi.org/10.1186/s12882-021-02586-6https://doaj.org/toc/1471-2369Abstract Background Kidney dysfunction occurs in severe COVID-19, and is a predictor of COVID-19 mortality. Whether kidney dysfunction causes severe COVID-19, and hence is a target of intervention, or whether it is a symptom, is unclear because conventional observational studies are open to confounding. To obtain unconfounded estimates, we used Mendelian randomization to examine the role of kidney function in severe COVID-19. Methods We used genome-wide significant, uncorrelated genetic variants to predict kidney function, in terms of estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR), and then assessed whether people with genetically instrumented higher eGFR or lower UACR, an indication of better kidney function, had a lower risk of severe COVID-19 (8779 cases, 1,001,875 controls), using the largest available cohorts with extensive genotyping. For comprehensiveness, we also examined their role in COVID-19 hospitalization (24,274 cases, 2,061,529 controls) and all COVID-19 (1,12,612 cases, 2,474,079 controls). Results Genetically instrumented higher eGFR was associated with lower risk of severe COVID-19 (odds ratio (OR) 0.90, 95% confidence interval (CI) 0.83, 0.98) but not related to COVID-19 hospitalization or infection. Genetically instrumented UACR was not related to COVID-19. Conclusions Kidney function appears to be one of the key targets for severe COVID-19 treatment. Use of available medications to improve kidney function, such as antihypertensives, might be beneficial for COVID-19 treatment, with relevance to drug repositioning.Jie V. ZhaoC. Mary SchoolingBMCarticleDiseases of the genitourinary system. UrologyRC870-923ENBMC Nephrology, Vol 22, Iss 1, Pp 1-6 (2021) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
Diseases of the genitourinary system. Urology RC870-923 |
spellingShingle |
Diseases of the genitourinary system. Urology RC870-923 Jie V. Zhao C. Mary Schooling Using genetics to understand the role of kidney function in COVID-19: a mendelian randomization study |
description |
Abstract Background Kidney dysfunction occurs in severe COVID-19, and is a predictor of COVID-19 mortality. Whether kidney dysfunction causes severe COVID-19, and hence is a target of intervention, or whether it is a symptom, is unclear because conventional observational studies are open to confounding. To obtain unconfounded estimates, we used Mendelian randomization to examine the role of kidney function in severe COVID-19. Methods We used genome-wide significant, uncorrelated genetic variants to predict kidney function, in terms of estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR), and then assessed whether people with genetically instrumented higher eGFR or lower UACR, an indication of better kidney function, had a lower risk of severe COVID-19 (8779 cases, 1,001,875 controls), using the largest available cohorts with extensive genotyping. For comprehensiveness, we also examined their role in COVID-19 hospitalization (24,274 cases, 2,061,529 controls) and all COVID-19 (1,12,612 cases, 2,474,079 controls). Results Genetically instrumented higher eGFR was associated with lower risk of severe COVID-19 (odds ratio (OR) 0.90, 95% confidence interval (CI) 0.83, 0.98) but not related to COVID-19 hospitalization or infection. Genetically instrumented UACR was not related to COVID-19. Conclusions Kidney function appears to be one of the key targets for severe COVID-19 treatment. Use of available medications to improve kidney function, such as antihypertensives, might be beneficial for COVID-19 treatment, with relevance to drug repositioning. |
format |
article |
author |
Jie V. Zhao C. Mary Schooling |
author_facet |
Jie V. Zhao C. Mary Schooling |
author_sort |
Jie V. Zhao |
title |
Using genetics to understand the role of kidney function in COVID-19: a mendelian randomization study |
title_short |
Using genetics to understand the role of kidney function in COVID-19: a mendelian randomization study |
title_full |
Using genetics to understand the role of kidney function in COVID-19: a mendelian randomization study |
title_fullStr |
Using genetics to understand the role of kidney function in COVID-19: a mendelian randomization study |
title_full_unstemmed |
Using genetics to understand the role of kidney function in COVID-19: a mendelian randomization study |
title_sort |
using genetics to understand the role of kidney function in covid-19: a mendelian randomization study |
publisher |
BMC |
publishDate |
2021 |
url |
https://doaj.org/article/3c669e3ede624482ad9dd9feade77c76 |
work_keys_str_mv |
AT jievzhao usinggeneticstounderstandtheroleofkidneyfunctionincovid19amendelianrandomizationstudy AT cmaryschooling usinggeneticstounderstandtheroleofkidneyfunctionincovid19amendelianrandomizationstudy |
_version_ |
1718429041468375040 |